China’s top drugmaker jumps on HK listing
Shares of China’s largest drugmaker, Hengrui Pharmaceuticals, opened 29% higher in its Hong Kong debut after raising HKD 9.9 billion, making it one of the year’s largest listings. The proceeds will support its global R&D in oncology, cardiometabolic, and neurological drugs, as the firm seeks its first overseas approvals. The IPO adds momentum to Hong Kong’s rebounding capital markets.